Cited by 96Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomicsGenomics and Rare Diseases

Massively parallel phenotyping of coding variants in cancer with Perturb-seq

Open access
Ursu, Oana, Neal, James T., Shea, Emily, Thakore, Pratiksha I., Jerby-Arnon, Livnat, Nguyen, Lan, Dionne, Danielle, Diaz, Celeste +13 more·2022·Nature Biotechnology

Abstract

Genome sequencing studies have identified millions of somatic variants in cancer, but it remains challenging to predict the phenotypic impact of most. Experimental approaches to distinguish impactful variants often use phenotypic assays that report on predefined gene-specific functional effects in bulk cell populations. Here, we develop an approach to functionally assess variant impact in single cells by pooled Perturb-seq. We measured the impact of 200 TP53 and KRAS variants on RNA profiles in over 300,000 single lung cancer cells, and used the profiles to categorize variants into phenotypic subsets to distinguish gain-of-function, loss-of-function and dominant negative variants, which we validated by comparison with orthogonal assays. We discovered that KRAS variants did not merely fit into discrete functional categories, but spanned a continuum of gain-of-function phenotypes, and that their functional impact could not have been predicted solely by their frequency in patient cohorts. Our work provides a scalable, gene-agnostic method for coding variant impact phenotyping, with potential applications in multiple disease settings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-021-01160-7

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. Hotelling, H. (1931). The Generalization of Student's Ratio. The Annals of Mathematical Statistics 2, 360-378.
  2. Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D.A., Rynn, C., et al. (2015). A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. eLife 4. Kamburov, A., Lawrence, M.S., Polak, P., Leshchiner, I., Lage, K., Golub, T.R., Lander, E.S., and Getz, G. (2015). Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc. Natl. Acad. Sci. U. S. A. 112, E5486-E5495.
  3. Rotem, A., Janzer, A., Izar, B., Ji, Z., Doench, J.G., Garraway, L.A., and Struhl, K. (2015). Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proc. Natl. Acad. Sci. U. S. A. 112, 5708-5713.

Cited by

Sorted by citations

Authors
Ursu, O., Neal, J. T., Shea, E., Thakore, P. I., Jerby-Arnon, L., Nguyen, L., Dionne, D., Diaz, C., Bauman, J., Mosaad, M. M., Fagre, C., Lo, A., McSharry, M., Giacomelli, A. O., Ly, S. H., Rozenblatt-Rosen, O., Hahn, W. C., Aguirre, A. J., Berger, A. H., Regev, A., & Boehm, J. S.
Affiliations
  • Broad Institute (US)
  • Fred Hutch Cancer Center (US)
Corresponding author
  • Regev, Aviv
  • Boehm, Jesse S.
Venue
Nature Biotechnology
Published
2022-01-20
Volume
40
Issue
6
Pages
896-905
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
OpenAlex
W4206229719
Cited by
96
References
16
Citations by year
2026: 15 · 2025: 12 · 2024: 27 · 2023: 24 · 2022: 12 · 2021: 6
FWCI
8.19
Type
journal article
Language
en
Open access
Locations
  • Nature Biotechnology (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nd)
  • PubMed (publishedVersion)
Funders
  • Howard Hughes Medical Institute
  • Broad Institute (Broadnext10 internal award)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
Perturb-seq, somatic mutations, TP53 variants, KRAS mutation, lung cancer, gain-of-function mutations, loss-of-function mutations, dominant-negative mutant, cancer genomics
MeSH terms
Chromosome Mapping, Humans, Lung Neoplasms, Phenotype, Proto-Oncogene Proteins p21(ras)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review